openPR Logo
Press release

CD BioSciences Announces Comprehensive Range of Nervous System Tissue Microarrays

03-25-2024 07:44 PM CET | Health & Medicine

Press release from: ABNewswire

CD BioSciences Announces Comprehensive Range of Nervous System

CD BioSciences announces Nervous System Tissue Microarrays for neuroscience research.
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, proudly announces an extensive portfolio of Nervous System Tissue Microarrays [https://www.bioimagingtech.com/nervous-system-tissue-microarrays.html] designed to support neuroscience research. This comprehensive collection provides researchers with a unique resource to study various neurological conditions and accelerate their investigations into neurological diseases and disorders.

CD Bioscience has been developing imaging technologies for many years and uses high content imaging, nanoparticle imaging, imaging flow cytometry, time-lapse imaging and other technologies to image cellular structures, cell migration, cell proliferation, pathogen infection mechanisms and protein molecule interactions. In addition, the company has a team of professionals with extensive experience in the imaging field and can provide customers with personalized imaging services to meet their research needs in the fields of biology, microbiology, medicine and food.

CD BioSciences now offers a comprehensive portfolio of Nervous System Tissue Microarrays, including Brain Tissue Microarrays and Head & Neck Tissue Microarrays. This comprehensive offering provides researchers with a powerful tool for studying various neurological disorders, including brain tumors, head and neck cancers, and neurodegenerative diseases.

For example, Multiple Sites of Normal Brain Tissue Microarray, 80 Cases, 26 Cores (Catalog NO. NBCT003) is a tissue microarray consisting of normal brain tissue from multiple sites, including different regions of the brain. It contains 3 cases each of frontal lobe, apical lobe, occipital lobe, temporal lobe, midbrain, pons, medulla oblongata, thalamus opticus, cerebellum, hippocampus, callositas, optic nerves, and spinal cord tissue, and 1 case of caudate nucleus. Each case has duplicate cores for each block.

Head and Neck Cancer Tissue Microarray, 80 Cases, 80 Cores (Catalog NO. NBCT044) can be used for IHC, ISH and other routine histology procedures. This tissue microarray is created using head and neck cancer samples and tongue tissue, and it includes 57 cases of squamous cell carcinoma, 3 cases of undifferentiated carcinoma, 1 case of sarcomatoid carcinoma, 8 cases of metastatic squamous cell carcinoma, 7 cases of tongue tissue, 2 cases of salivary gland tissue, and 1 case each of sublingual gland tissue and parotid gland tissue. Each case has one nuclear core.

These microarrays allow researchers to conduct efficient and cost-effective studies on various neurological conditions, accelerating discoveries with the potential to improve patient outcomes. In addition, CD BioSciences is continually expanding its portfolio to provide scientists with more efficient tools to analyze multiple nervous system tissue samples simultaneously, facilitating in-depth investigations into disease mechanisms, biomarker discovery, and drug development.

With a focus on innovation and precision, CD BioSciences has developed state-of-the-art Nervous System Tissue Microarrays to allow scientists better study nervous tissue samples and advance neuroscience research. To learn more about the new products, please visit https://www.bioimagingtech.com/nervous-system-tissue-microarrays.html.

About CD BioSciences

CD BioSciences is a biotechnology company committed to the development of imaging technology for many years. Its scientists can utilize high-content imaging, nanoparticle imaging, imaging flow cytometry, time-lapse imaging, and other techniques to image cell structure, cell migration, cell proliferation, pathogen infection mechanisms, and interactions between protein molecules.

Media Contact
Company Name: CD BioSciences
Contact Person: Michelle Moser
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cd-biosciences-announces-comprehensive-range-of-nervous-system-tissue-microarrays]
State: New York
Country: United States
Website: https://www.bioimagingtech.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CD BioSciences Announces Comprehensive Range of Nervous System Tissue Microarrays here

News-ID: 3441535 • Views:

More Releases from ABNewswire

Lone Wolf Siding Emerges as the Best Siding Company in New Orleans Offering Premium Siding, Patios, and Pergolas
Lone Wolf Siding Emerges as the Best Siding Company in New Orleans Offering Prem …
Lone Wolf Siding is the best siding company in New Orleans, Louisiana. Image: https://www.abnewswire.com/upload/2025/09/3522ab792132a4d3ddba57316984a0de.jpg Lone Wolf Siding, a trusted siding contractor in New Orleans, proudly announces its expanded offerings designed to protect and enhance homes across Louisiana. With a strong foundation in expert siding installation and repair, the company now provides homeowners with a full suite of exterior solutions, including patios and pergolas, all backed by exceptional craftsmanship and a 100% satisfaction
Buerger's Disease Pipeline 2025: Pioneering Clinical Developments by 3+ Global Leaders - DelveInsight | Featuring Antidote Therapeutics, K-STEMCELL, Caladrius Biosciences
Buerger's Disease Pipeline 2025: Pioneering Clinical Developments by 3+ Global L …
DelveInsight's, "Buerger's Disease - Pipeline Insight, 2025," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Buerger's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. As Buerger's Disease increasingly affects populations worldwide and is linked
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical Progress by 8+ Global Leaders - DelveInsight | Featuring Ultragenyx Pharmaceutical Inc, JCR Pharmaceuticals Co., Ltd., GC Biopharma Corp, D
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical Progress by 8+ Glob …
DelveInsight's, "Mucopolysaccharidosis III - Pipeline Insight, 2025" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Mucopolysaccharidosis III pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Mucopolysaccharidosis III (MPS III) is emerging as a significant global
Ovarian Cancer Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis
Ovarian Cancer Clinical Trials, Companies, Therapeutic Assessment, Emerging Ther …
Ovarian Cancer companies are Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, and others. Ovarian Cancer Pipeline constitutes 180+ key companies continuously working towards developing 200+ Ovarian Cancer treatment therapies, analyzes DelveInsight. Ovarian Cancer Overview: Ovarian cancer is the deadliest gynecological cancer and the

All 5 Releases


More Releases for BioSciences

Nanostructured Drug Market Poised for Growth with Advancements in Targeted Deliv …
Nanostructured Drug Market Overview Nanostructured Drug Market is projected to grow significantly during the forecast period, driven by advancements in nanotechnology and increasing demand for targeted drug delivery systems. The latest report (2025-2032) on the Nanostructured Drug Market by Coherent Market Insights offers an in-depth analysis of market trends, growth factors, challenges, and competition. It explores market size, revenue, production, consumption, and CAGR, using reliable research methods for accuracy. The report also
CRISPR-Based Diagnostics Market for Infectious Diseases & Cancer Detection By 20 …
Global CRISPR-Based Diagnostics Market reached at a CAGR during the forecast period 2024-2031. Crispr-Based Diagnostics Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate
CRISPR-Based Diagnostics Market: Global Type, Trends, Service, Growth, Opportuni …
The CRISPR-Based Diagnostics Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach. Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/crispr-based-diagnostics-market What is the projected
CRISPR Based Diagnostics Market Growing Rapidly by 2031 - Sherlock Biosciences, …
DataM Intelligence has published a new research report on "CRISPR Based Diagnostics Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. Get a Free Sample Research PDF
Glycated Albumin Market to See Booming Growth 2024-2031 | Lifespan Biosciences, …
Glycated Albumin Market Trends Overview 2024-2031: A new Report by Coherent Market Insights, titled "Glycated Albumin Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the Glycated Albumin market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. This report has a complete table of contents, figures, tables, and charts, as well as insightful
Congenital Adrenal Hyperplasia Market to Witness Growth by 2032, Estimates Delve …
DelveInsight's "Congenital Adrenal Hyperplasia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Congenital Adrenal Hyperplasia, historical and forecasted epidemiology as well as the Congenital Adrenal Hyperplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Congenital Adrenal Hyperplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here: https://www.delveinsight.com/sample-request/congenital-adrenal-hyperplasia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of